No Data
fujifilm holdings corporation unsponsored adr (301258.SZ): Repurchased 0.3371% of the shares accumulated.
Guolonghui September 2nd, Fujilai (301258.SZ) announced that as of August 31, 2024, the company has repurchased a total of 309,000 shares of the company through the special stock buyback account in a centralized competitive trading manner, accounting for 0.3371% of the total share capital of the company. The highest fill price was 26.18 yuan per share, and the lowest fill price was 20.60 yuan per share, with a total fund usage of 7,152,460.00 yuan (excluding transaction costs). The company's share buyback implementation complies with relevant laws and regulations and the established share buyback program.
We Think You Can Look Beyond Suzhou Fushilai Pharmaceutical's (SZSE:301258) Lackluster Earnings
Suzhou Fushilai Pharmaceutical: Summary of Half-Year Report in 2024.
Suzhou Fushilai Pharmaceutical: Half-year report for the year 2024.
fujifilm holdings corporation unsponsored adr (301258.SZ): net loss of 0.349 million yuan in the first half of the year, turning to a loss on a year-on-year basis
On August 22nd, Fujifilm Holdings Corporation unsponsored adr (301258.SZ) released its semi-annual report, with revenue of 0.217 billion yuan, a year-on-year decrease of 27.14%. Net loss was 0.349 million yuan, a year-on-year change from profit to loss. Non-GAAP net loss was 5.669 million yuan, a year-on-year change from profit to loss. Basic earnings per share was -0.0038 yuan.
Fujilai (301258.SZ): Currently, the company does not have any business related to cardiovascular and cerebrovascular diseases.
On August 13th, Golon Hui reported that Fujilai (301258.SZ) mainly engages in the research and development, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and raw materials for health products. The main products include the series of thiophene acetic acid, phosphatidylcholine, and dipeptide. The company currently has no related business in cardiovascular and cerebrovascular diseases.
No Data
No Data